Pharmaceutical compositions for cell therapy of pigmentation disorders

A technology of pigmentation and composition, applied in the direction of drug combination, cell culture support/coating, animal cells, etc., can solve the problems of low recoloration and side effects

Inactive Publication Date: 2009-01-21
MODERN CELL & TISSUE TECH
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the therapy may induce lower repigmentation and side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compositions for cell therapy of pigmentation disorders
  • Pharmaceutical compositions for cell therapy of pigmentation disorders
  • Pharmaceutical compositions for cell therapy of pigmentation disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1: Isolation and culture of melanocytes, keratinocytes and fibroblasts

[0051] Melanocytes, keratinocytes, and fibroblasts isolated from normal human skin tissue and cultured.

Embodiment 1-1

[0052] Example 1-1: Isolation and culture of melanocytes

[0053] The skin tissue was washed 8 times with phosphate buffered saline (WelGENE) containing 50 μg / ml antibiotic (gentamycin, Gibco) to remove coagulated blood and contaminants. The fat layer in the dermis of the skin tissue was removed, and the tissue was cut into 5 mm size, and the cut tissue was incubated with 1 mg / ml dispase (Roche) at 4° C. for 16 hours. Then, the epidermis was separated from the skin tissue, washed with phosphate buffer solution and incubated with trypsin-EDTA solution (0.05% trypsin-0.53 mM EDTA·4Na, Gibco) for 30 minutes at 37°C. Several aspirations of the trypsin-EDTA solution containing the epidermis were used to separate the cells (melanocytes and keratinocytes) from the epidermis.

[0054] MGM-3 (Cambrex) was added as a melanocyte medium to the trypsin-EDTA solution containing isolated melanocytes and keratinocytes and the resultant was transferred to a 50 ml test tube, followed by centr...

Embodiment 1-2

[0055] Embodiment 1-2: Isolation and culture of keratinocytes

[0056] The skin tissue was washed 8 times with phosphate buffered saline (WelGENE) containing 50 μg / ml antibiotic (gentamycin, Gibco) to remove coagulated blood and contaminants. The fat layer in the dermis of the skin tissue was removed, and the tissue was cut into a size of 5 mm, and the cut tissue was physically stimulated with 10 ml of trypsin solution (0.125% trypsin: versene=1: 1, Gibco ) at room temperature for 45 minutes to separate keratinocytes. To the trypsin solution containing the isolated cells, 0.1 mg / ml of trypsin inhibitor (Gibco) was added and transferred to a 50 ml tube, followed by centrifugation at 300 xg. After removing the supernatant, KGM (Cambrex) as a keratinocyte medium was added to homogenize the isolated cells and the homogenization solution (containing 3 × 10 5 cells) were aliquoted into 100mm Petri dishes. at 37°C in CO 2 Cell cultures were performed in an incubator with medium...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a pharmaceutical composition for cell therapy of pigmentation disorders, which comprises as an active ingredient (a) melanocytes and keratinocytes, or (b) melanocytes and fibroblasts. The cell therapy composition of this invention allows for the first time to treat pigmentation disorders through cell therapy regimen. The present composition comprises as active ingredients a mixed cell preparation of melanocytes and keratinocytes or a mixed cell preparation of melanocytes and fibroblasts such that it induces very effectively pigmentation to treat diseases associated with hypopig mentation such as vitiligo.

Description

technical field [0001] The present invention relates to pharmaceutical cell therapy compositions and pigmented skin remodeling models for the treatment of pigmentation disorders. Background technique [0002] Therapies for pigmentation disorders such as Vitiligo include chemotherapy and surgery. Chemotherapy is usually performed by applying or topically applying steroids to the skin, or administering photosensitizers and exposing the patient to ultraviolet light. However, this therapy may induce lower repigmentation and side effects. Surgical treatment is performed by excision of the epidermis showing leukoplakia symptoms and transplantation of normal autologous epidermis to the excised part. [0003] Korean Patent No. 293736 discloses Meliae Cortex extract including sugar-binding protein for treating vitiligo. Korean Patent Application No. 2003-0056823 discloses photodynamic therapy of administering a photosensitizer and locally irradiating chemical light for treating vi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61K35/12A61K35/36
CPCA61K35/36A61K35/12C12N5/0698C12N2502/091C12N2502/094C12N2502/1323C12N2533/52C12N2533/54A61P17/00A61K35/56A61K38/17
Inventor 朴基淑李秀贤黄智勋朴钻雄
Owner MODERN CELL & TISSUE TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap